PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33502001-0	2021	Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.	ruxolitinib	12-23	pericentriolar material 1	Homo sapiens	62-66	
32279331-1	2020	We report on 18 patients with myeloid neoplasms and associated tyrosine kinase (TK) fusion genes on treatment with the TK inhibitors (TKI) ruxolitinib (PCM1-JAK2, n=8; BCR-JAK2, n=1) and imatinib, nilotinib or dasatinib (ETV6-ABL1, n=9).	ruxolitinib	139-150	pericentriolar material 1	Homo sapiens	152-156	
26202607-0	2015	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.	ruxolitinib	12-23	pericentriolar material 1	Homo sapiens	50-54	
25260694-0	2015	Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.	ruxolitinib	42-53	pericentriolar material 1	Homo sapiens	80-84	
23630205-0	2013	Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.	ruxolitinib	12-23	pericentriolar material 1	Homo sapiens	75-79	
22899477-0	2012	Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.	ruxolitinib	0-11	pericentriolar material 1	Homo sapiens	126-130	
34707996-2	2021	Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but the efficacy is variable.	ruxolitinib	42-53	pericentriolar material 1	Homo sapiens	89-93	
34707996-3	2021	Here, we report two patients diagnosed with MPN with PCM1-JAK2 fusion who were treated with ruxolitinib-based regimen, including the first case of ruxolitinib combined with pegylated interferon (Peg-IFN), and we conduct a literature review.	ruxolitinib	92-103	pericentriolar material 1	Homo sapiens	53-57	
34707996-3	2021	Here, we report two patients diagnosed with MPN with PCM1-JAK2 fusion who were treated with ruxolitinib-based regimen, including the first case of ruxolitinib combined with pegylated interferon (Peg-IFN), and we conduct a literature review.	ruxolitinib	147-158	pericentriolar material 1	Homo sapiens	53-57	
34547879-0	2021	(Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report).	ruxolitinib	85-96	pericentriolar material 1	Homo sapiens	14-18